Creating a new targeted treatment for prostate cancer
Official title: Development of an Innovative PSMA-Targeted Small Molecule Prodrug for Prostate Cancer
Funded at Cancer Targeted Technology, LLC · NIH-10910547 · Data updated 2026-11-12
This study is testing a new treatment for advanced prostate cancer that aims to deliver a powerful cancer-fighting drug directly to the cancer cells, which could help improve results and lessen side effects for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cancer Targeted Technology, LLC NIH-funded |
| Lab location | 1 site (Woodinville, United States) |
| Project start | September 2, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $400,000 |
| NIH project number | 1R44CA290973-01 |
| Project ID | NIH-10910547 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are men diagnosed with metastatic castration-resistant prostate cancer who have limited treatment options.
✕Less likely to help
Patients with early-stage prostate cancer or those who do not express the PSMA biomarker may not benefit from this research.
What this research studies
This research focuses on developing a novel small molecule prodrug that targets prostate-specific membrane antigen (PSMA) to treat metastatic castration-resistant prostate cancer (mCRPC). The approach involves conjugating a potent cancer-fighting agent, monomethyl auristatin E (MMAE), to a targeting molecule that specifically binds to cancer cells, minimizing damage to healthy cells. By enhancing the delivery of the drug directly to the cancer cells, this method aims to improve treatment efficacy while reducing side effects. Patients may have the opportunity to participate in clinical trials evaluating this innovative treatment.
Why it matters
Potential benefit: If successful, this research could provide a more effective and less toxic treatment option for patients with advanced prostate cancer.
How similar studies have gone: While there have been successful applications of antibody-drug conjugates in other cancers, this specific approach using small molecule drug conjugates for mCRPC is relatively novel.
Where this research is happening
-
Cancer Targeted Technology, LLC
Woodinville, United States Active
Researchers
- Principal investigator: Langton-Webster, Beatrice — Cancer Targeted Technology, LLC
- Study coordinator: Langton-Webster, Beatrice
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.